1. Introduction

No-fault biotechnology injury compensation schemes concern legal mechanisms through which individuals who suffer injuries from biotechnology-related products, medical interventions, or scientific procedures can obtain compensation without having to prove that a manufacturer, healthcare professional, researcher, or public authority was negligent.

In Morocco, this subject is particularly important because biotechnology is increasingly relevant to:

Vaccine development and immunisation programmes.

Genetic testing and genomic research.

Biopharmaceuticals and biological medicines.

Cell and gene therapies.

Clinical trials involving biotechnology products.

Monoclonal antibodies and other advanced biological treatments.

Medical biotechnology and regenerative medicine.

The central legal issue is whether a person injured by an authorised biotechnology product or medical intervention can receive compensation simply by establishing that the injury occurred and was causally connected to the relevant product or intervention.

An important legal distinction: Morocco should not automatically be described as having a comprehensive, dedicated no-fault compensation scheme for all biotechnology injuries. Its legal framework must instead be examined through product liability, civil responsibility, pharmaceutical regulation, public-health law, medical liability, insurance, and any applicable special compensation arrangements.

This distinction matters because a no-fault compensation system is fundamentally different from an ordinary civil lawsuit: the claimant does not need to establish negligence, although causation, injury, eligibility, and statutory exclusions may still need to be proved.

2. Legal and Constitutional Framework in Morocco

Morocco's approach to biotechnology injury compensation is influenced by several legal principles.

A. Constitutional protection of health and bodily integrity

The Constitution of Morocco of 2011 recognises the right to healthcare and access to medical treatment, particularly through Article 31. Constitutional protections concerning physical integrity, dignity, and equality also inform the state's responsibility to protect individuals against health-related risks.

These principles support arguments for effective remedies when individuals suffer serious injuries connected with medical biotechnology.

However, constitutional recognition of healthcare rights does not, by itself, establish an automatic right to no-fault compensation for every adverse biological or pharmaceutical reaction.

B. Dahir of Obligations and Contracts (DOC), 1913

The Dahir forming the Code of Obligations and Contracts is an important foundation of Moroccan civil liability.

Its general principles address:

Liability arising from personal fault.

Damage caused to another person.

Causation between wrongful conduct and injury.

Responsibility for acts of others.

Responsibility associated with things under a person's control.

These principles can become relevant where a defective vaccine, contaminated biological medicine, unsafe laboratory procedure, or improperly administered biotechnology treatment causes injury.

Nevertheless, ordinary civil liability generally requires the claimant to establish the relevant legal basis for responsibility. It is not equivalent to a universal no-fault compensation arrangement.

3. Special Protection Under Law No. 28-13 of 2015

One of the most important laws for no-fault biotechnology injury compensation in Morocco is Law No. 28-13 concerning the protection of persons participating in biomedical research.

It establishes protections for individuals participating in biomedical research, including clinical investigations involving medicines, medical devices, and biological products.

The law is particularly significant because it creates a statutory compensation obligation for research-related injuries.

A. Article 34: Compensation for research-related injury

Article 34 provides that the sponsor (promoteur) is responsible for damage affecting the health of a research participant during the research or after its termination or completion, provided that a causal connection between the research and the damage is established.

Its principal requirements are:

The individual must have participated in the relevant biomedical research.

The participant must have suffered injury affecting their health.

A causal relationship between the research and the injury must be established.

The sponsor must guarantee full compensation.

In the event of death, compensation is payable to the participant's legal successors.

The sponsor must maintain insurance covering the civil liability arising from the research.

The provision is especially important because it does not make proof of the sponsor's negligence an express condition of compensation.

It therefore creates a no-fault-like statutory compensation mechanism, although causation must still be demonstrated.

Ma Loi+2

B. Mandatory insurance

Article 34 requires the sponsor to subscribe to and renew insurance covering the civil liability associated with the particular research.

This insurance must also cover the civil liability of investigators and other persons involved in the research, irrespective of their legal status or contractual relationship with the sponsor.

The administration may suspend or withdraw authorisation for biomedical research where the sponsor fails to obtain or renew the required insurance.

This requirement is significant because it reduces the possibility that an injured research participant will be left without compensation merely because the sponsor lacks sufficient financial resources.

C. Compensation irrespective of when injury becomes apparent

Article 34 expressly covers injuries occurring during research and those becoming apparent after research has been stopped or completed.

It also states that compensation is guaranteed irrespective of the period separating the research from the manifestation of the injury.

This is particularly relevant to biotechnology because certain adverse effects may emerge long after exposure to an experimental biological treatment.

For example:

Delayed immune-system complications.

Long-term complications following cell therapy.

Adverse genetic or biological consequences.

Delayed reactions to experimental medicines.

Complications arising from investigational biological devices.

The provision does not, however, remove the requirement to establish causation.

4. Product Liability and Biotechnology Injuries

Another central source of protection is Law No. 24-09 of 2011, which introduced defective-product liability provisions into the Moroccan Dahir of Obligations and Contracts.

These provisions appear in Articles 106-1 to 106-14.

They are important for biotechnology products because they can apply to defective medicines, vaccines, biological preparations, diagnostic products, and other products falling within the statutory definition.

A. Article 106-1: Producer liability

Article 106-1 provides that a producer is responsible for damage caused by a defect in its product.

This creates a form of strict product liability: the injured person does not have to establish that the manufacturer acted negligently if the statutory conditions for defective-product liability are satisfied.

B. Article 106-3: Definition of a defective product

A product is defective when it does not provide the safety that a person is legitimately entitled to expect, considering the circumstances, including:

How the product is presented.

The use reasonably expected of the product.

The time at which the product was placed on the market.

For biotechnology, this could include a vaccine with an unsafe manufacturing defect, a contaminated biological medicine, or a diagnostic product that presents an unacceptable safety risk.

C. Article 106-7: Proof of damage

The injured person must prove the damage caused by the defective product.

This is a crucial limitation. The claimant does not need to prove negligence, but must establish the injury and its connection to a product defect.

D. Article 106-8: Regulatory approval is not an automatic defence

A particularly important provision is Article 106-8.

It recognises that a producer may remain responsible even when the product was manufactured in accordance with existing technical standards or received administrative authorisation.

This means that regulatory approval does not automatically eliminate civil liability.

E. Article 106-9: Statutory defences

A producer may avoid liability under this chapter by proving specified circumstances, including:

It did not place the product on the market.

The defect did not exist when the product was placed into circulation.

The product was not manufactured or distributed in the relevant commercial activity.

The defect resulted from compliance with mandatory government requirements.

The defect could not have been discovered given the scientific and technical knowledge available when the product was marketed.

The final defence is particularly relevant to advanced biotechnology, where scientific knowledge may develop rapidly.

F. Article 106-10: Full compensation

Article 106-10 requires the responsible person to repair the entirety of the damage caused to the victim.

Article 106-11 permits reduction or exclusion of producer liability in certain circumstances where the victim's fault contributed to the damage.

Article 106-12 provides that the producer's responsibility towards the victim is not reduced merely because a third party contributed to the damage.

Article 106-13 prevents the producer or importer from excluding or limiting liability towards the victim through contractual clauses.

Article 106-14 preserves other rights available under ordinary contractual, tort, and special liability regimes.

WIPO+3

5. Pharmaceutical Regulation and Biotechnology Safety

Morocco's pharmaceutical regulatory framework is another important component of injury prevention and compensation.

A. Law No. 17-04 of 2006

Law No. 17-04 establishes the Code of Medicines and Pharmacy.

It regulates matters including:

Pharmaceutical manufacturing.

Medicine registration.

Quality control.

Pharmaceutical distribution.

Importation of medicines.

Regulatory supervision.

Conditions for placing medicines on the market.

Article 8 is particularly relevant because marketing authorisation depends on prior testing and the existence of manufacturing and control methods capable of ensuring product quality.

For biotechnology products, these requirements are important for ensuring the safety and quality of vaccines, biological medicines, and other pharmaceutical preparations.

However, pharmaceutical authorisation is not itself a no-fault compensation mechanism.

WIPO+2

B. Pharmacovigilance and adverse-event reporting

Pharmacovigilance provides a mechanism for identifying and monitoring adverse reactions associated with medicines.

In biotechnology, adverse-event monitoring is particularly important because biological products can produce complex immune responses and other effects that may not be immediately apparent.

An adverse-event report may help establish:

The identity of the product administered.

The date and circumstances of administration.

The nature of the injury.

The timing of the adverse reaction.

Whether similar reactions have been reported.

Whether further medical investigation is required.

A pharmacovigilance report is useful evidence, but does not automatically establish legal causation or entitlement to compensation.

6. Constitutional and Administrative Responsibility of the State

The Moroccan state may also face legal claims arising from injuries associated with public vaccination programmes, public-health interventions, and regulatory decisions.

Article 31 of the Constitution provides an important constitutional foundation for the protection of access to healthcare.

State responsibility may arise in circumstances involving:

Negligent public-health administration.

Failure to comply with safety obligations.

Defective administration of vaccines.

Failure to provide appropriate medical supervision.

Improper regulatory conduct.

Other legally recognised forms of public-service liability.

A particularly significant issue is whether the state may be held responsible without proof of administrative fault when an individual suffers an exceptional injury from an officially authorised vaccination programme.

This question has received judicial attention in Morocco through COVID-19 vaccine litigation.

7. Important Moroccan Case Law

Moroccan judicial practice is particularly important because it demonstrates the difference between ordinary fault-based liability and compensation based on the risks of medical interventions.

Case 1: AstraZeneca COVID-19 Vaccine Injury Litigation (2024)

Important Moroccan vaccine-liability case

Court: Administrative Court of Rabat, first instance, February 2024.

Subject: Guillain-Barré syndrome following administration of the AstraZeneca COVID-19 vaccine.

Facts:

A Moroccan woman experienced serious health complications following administration of the AstraZeneca COVID-19 vaccine. She brought proceedings against the Moroccan Ministry of Health, seeking compensation for her injuries.

The claimant argued that the state should bear responsibility for injuries associated with a vaccine that had been authorised and promoted through the national vaccination programme.

Decision at first instance:

The Administrative Court of Rabat reportedly ordered the state to pay MAD 250,000 in compensation.

The court adopted reasoning based on responsibility for vaccination-related risks without requiring the claimant to prove administrative fault.

It emphasised the state's responsibility to protect citizens against risks associated with vaccination programmes.

Appeal:

On 24 July 2024, the Administrative Court of Appeal in Rabat overturned the first-instance judgment.

The appellate court's reasoning was not available in the contemporaneous reporting, so its precise legal grounds cannot safely be stated.

Legal significance:

This litigation is important for three reasons:

It demonstrates that vaccine-related injuries can raise questions of state responsibility beyond ordinary manufacturer liability.

The first-instance reasoning recognised the possibility of compensation without proof of administrative fault.

The appellate reversal demonstrates that such compensation cannot be treated as an established general entitlement under Moroccan law.

This is therefore an important example of judicial debate over no-fault vaccine compensation, rather than a final precedent establishing a nationwide vaccine injury compensation scheme.

Source: Médias24, 26 July 2024.

Numéro un de l'information économique marocaine+1

Case 2: Moroccan defective-product liability jurisprudence under Article 106-1

Court: Moroccan Court of Cassation.

Legal provision: Article 106-1 of the Dahir of Obligations and Contracts.

Article 106-1 establishes producer responsibility for damage resulting from a defective product.

Moroccan legal databases report numerous Court of Cassation decisions applying this provision.

Legal principle:

The legal inquiry focuses on whether the product was defective and whether the defect caused the claimant's injury, rather than requiring proof of negligence in manufacturing.

Application to biotechnology:

The same legal framework may be relevant to claims involving:

Defective vaccines.

Contaminated biological medicines.

Unsafe biotechnology diagnostic products.

Defective pharmaceutical preparations.

Other defective medical biotechnology products.

However, these general product-liability decisions should not be presented as judgments specifically concerning genetic therapy or vaccine injuries unless the underlying judgments establish that connection.

Source: Moroccan legislation and judicial references concerning Article 106-1.

IALAW+2

Case 3: Statutory compensation under Law No. 28-13

There is an important distinction between a judicial precedent and a statutory compensation entitlement.

Article 34 of Law No. 28-13 establishes the sponsor's obligation to compensate participants in biomedical research where a causal connection between the research and injury is proved.

The provision also requires insurance covering the relevant civil liability.

Although it provides a clear statutory basis for compensation, I have not identified a sufficiently documented reported Moroccan judgment applying Article 34 to a particular biotechnology injury.

Accordingly, Article 34 should be treated as an operative statutory authority, not as an invented court precedent.

Ma Loi+1

8. Difference Between No-Fault Compensation and Strict Product Liability

The distinction is essential to understanding Moroccan law.

The distinction can be illustrated through two examples.

Example A: Experimental gene therapy

A participant receives an experimental gene therapy during an authorised clinical investigation and subsequently suffers serious biological complications.

If a causal relationship between the research and the injury is established, Article 34 may require the sponsor to compensate the participant without proof of negligence.

Example B: Defective biological medicine

A patient receives a commercially marketed biological medicine containing a manufacturing defect that causes serious injury.

The patient may bring a claim under Articles 106-1 onwards, establishing the defect, injury, and causal connection.

The claimant does not need to establish negligence, but must prove the statutory product-liability requirements.

9. Procedure for Claiming Compensation in Morocco

A person suffering biotechnology-related injury should consider the following procedure.

Medical documentation

Obtain medical records, laboratory reports, diagnostic results, hospital records, and medical assessments identifying the injury.

Identify the biotechnology product or intervention

Establish the manufacturer's identity, product batch number, date of administration, research protocol, and relevant healthcare institution.

Establish causation

Obtain expert medical evidence addressing whether the injury is attributable to the biological product, clinical investigation, or medical intervention.

Identify the responsible party

Determine whether the claim concerns the research sponsor, manufacturer, importer, healthcare provider, or public administration.

Identify the appropriate legal mechanism

Consider Article 34 of Law 28-13, Articles 106-1 onwards of the DOC, ordinary civil liability, or applicable administrative liability.

Seek compensation

Pursue the appropriate insurance claim, settlement procedure, or judicial proceedings, depending on the applicable legal basis.

10. Types of Compensation Available

Depending on the applicable legal regime and evidence, compensation may cover:

Article 34 of Law 28-13 specifically provides for full compensation for research-related injury and compensation to legal successors in the event of death.

Article 106-10 similarly requires full reparation of damage caused by defective products.

11. Major Legal Challenges in Morocco

Despite the existing statutory protections, several difficulties remain.

A. Scientific causation

Biotechnology injuries may involve complicated biological mechanisms. Establishing whether a particular vaccine, gene therapy, or biological medicine caused an injury can require extensive scientific evidence.

B. Delayed injuries

Some adverse effects may emerge years after exposure. Although Article 34 addresses delayed manifestation of research-related injuries, establishing the connection can remain difficult.

C. Absence of a general compensation fund

The research sponsor's insurance obligation under Article 34 is not equivalent to a government-administered national compensation fund covering every biotechnology injury.

D. Access to medical expertise

Victims may experience difficulties obtaining independent scientific opinions, particularly in complex cases involving genetics, immunology, and advanced biological therapies.

E. Cross-border biotechnology products

A biological medicine may be manufactured abroad, imported into Morocco, and administered in a Moroccan healthcare institution.

Determining the appropriate defendant, applicable law, jurisdiction, and insurance coverage may consequently become complicated.

F. Distinguishing unavoidable adverse reactions from product defects

A product can cause an adverse reaction without necessarily being defective. This distinction is particularly important for vaccines and biological medicines.

12. Recommendations for Reforming Morocco's No-Fault Biotechnology Compensation System

Morocco could consider developing a dedicated national biotechnology injury compensation framework.

The following reforms would strengthen protection:

1. National biotechnology injury compensation fund: Establish a government-supervised fund covering qualifying injuries caused by vaccines, gene therapies, cell therapies, and other designated biotechnology interventions.

2. No-fault eligibility criteria: Permit compensation without proof of negligence, subject to defined injury and causal-association requirements.

3. Independent scientific assessment: Establish multidisciplinary medical and scientific panels to evaluate causation.

4. Mandatory insurance: Extend appropriate financial protection beyond clinical research sponsors to other designated biotechnology interventions.

5. Transparent claims procedure: Introduce clear deadlines, accessible applications, reasoned decisions, and independent review.

6. Long-term injury monitoring: Develop systems for monitoring delayed adverse reactions and preserving relevant medical evidence.

7. Protection of vulnerable patients: Provide accessible procedures for children, persons with disabilities, and individuals suffering serious long-term complications.

8. Coordination with international standards: Consider relevant principles from WHO vaccine safety guidance and international clinical research protections.

9. Public accountability: Require publication of anonymised information concerning claims, compensation outcomes, and adverse-event trends.

10. Preservation of civil remedies: Ensure that receiving statutory compensation does not unnecessarily extinguish claims against manufacturers or other legally responsible parties.

13. Comparative Legal Perspective

Morocco's legal development can also be understood through comparison with other compensation systems.

These systems demonstrate different approaches to distributing the financial consequences of biotechnology and medical injuries. They should not be treated as interchangeable legal models.

14. Conclusion

Morocco has developed important legal protections for individuals suffering injuries associated with biotechnology and medical products.

Three legal foundations are particularly important:

Law No. 28-13 of 2015, Article 34: Establishes compensation and mandatory insurance obligations for injuries causally connected with biomedical research.

Law No. 24-09 of 2011 and DOC Articles 106-1 to 106-14: Establish producer liability for defective products without requiring proof of negligence.

The Moroccan Constitution and administrative liability principles: Provide a broader framework for considering state responsibility in public-health and vaccination-related disputes.

The 2024 AstraZeneca vaccine litigation is particularly significant because the first-instance court recognised a possible basis for compensation without proof of administrative fault, although that judgment was subsequently overturned on appeal.

The central legal conclusion is that Morocco has elements of no-fault and strict-liability protection, especially in biomedical research, but these do not amount to a comprehensive national no-fault biotechnology injury compensation scheme.

Developing a dedicated compensation fund, independent scientific assessment procedures, and broader insurance protection would help close this legal gap.

15. Principal Legal References and Research Sources

Constitution of the Kingdom of Morocco, 2011, particularly Article 31.

Dahir of Obligations and Contracts, 1913, as amended.

Law No. 24-09 of 2011 concerning product and service safety.

Law No. 28-13 of 2015 concerning protection of persons participating in biomedical research.

Law No. 17-04 of 2006 concerning the Code of Medicines and Pharmacy.

Law No. 131-13 concerning the practice of medicine.

Administrative Court of Rabat, AstraZeneca vaccine injury proceedings, February 2024; subsequent appellate judgment of 24 July 2024.

Useful primary and legal research sources:

Moroccan General Secretariat of Government – Legislation.

Moroccan Law No. 28-13 – Biomedical Research Protection.

WIPO – Moroccan Code of Obligations and Contracts.

WIPO – Law No. 17-04.

Médias24 – AstraZeneca vaccine compensation litigation (2024).

Academic note: This explanation distinguishes enacted legislation, reported judicial decisions, and proposed reforms. The full appellate judgment in the 2024 vaccine case and a reported judgment applying Article 34 should be obtained before making more specific claims about their judicial interpretation.